SCLC Tarlatamab Blood Collection
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Small-cell Lung Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Analysis of Blood Samples in Small Cell Lung Cancer Patients Treated With Tarlatamab
Overview
The overall objective of this project is to prospectively collect blood samples throughout treatment with tarlatamab in patients with small cell lung cancer (SCLC). These samples will then be analyzed through a variety of assays to better characterize tarlatamab in the real-world setting. The investigators will prospectively collect blood samples from 25 patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.
Primary outcome measures
- Number of blood samples collected to better characterize tarlatamab in real-world setting [Time frame: Days 1, 8, and 15 of tarlatamab and after each interval scan for disease assessment]
Eligibility criteria
Inclusion criteria
- Pathologically documented small cell lung cancer (SCLC) or neuroendocrine tumor
- Appropriate candidate for treatment with tarlatamab based on investigator discretion
- Age > 18 years
- Signed written informed consent including HIPAA according to institutional guidelines
Exclusion criteria
- Does not meet all inclusion criteria
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07468656 · Pro00119597